Zydus Just Bet Big on a Lung Disease Most People Haven't Heard Of
Zydus's U.S. subsidiary just inked a deal worth up to $475 million for a rare lung disease drug most people have never heard of. The option-and-license structure, the Indian pharma giant's quiet rare disease shopping spree, and what still needs to go right make this one worth watching.
A Rare Disease Gets a Big Check
Somewhere in the world, a person with a specific genetic mutation is slowly losing the ability to breathe. Their lungs are being eaten from the inside out by an enzyme their body can't control. There's no approved pill to stop it. And until this week, the most promising drug candidate for this condition didn't have a U.S. commercial partner.
Now it does. Sentynl Therapeutics, a U.S.-based subsidiary of India's Zydus Group, just signed an option-and-license deal for alvelestat, a drug being developed by UK-based Mereo BioPharma. The target: alpha-1 antitrypsin deficiency-associated lung disease, or AATD-LD. It's a mouthful, but the deal structure is surprisingly elegant.
The Disease That Eats Your Lungs
To understand why this deal matters, you need to understand the disease. Alpha-1 antitrypsin deficiency (let's just call it Alpha-1) is a genetic condition where your body doesn't produce enough of a protective protein. Think of that protein as a bodyguard for your lungs. Without enough of it, an enzyme called neutrophil elastase runs wild, chewing through lung tissue like termites through wood.
Patients with severe Alpha-1, particularly those carrying two copies of the Z mutation (called Pi*ZZ), develop progressive emphysema. Their lungs slowly lose the ability to exchange oxygen. The condition is rare, but it's devastating.
The current standard of care? Augmentation therapy: IV infusions of the missing protein, often weekly, for life. It's expensive, inconvenient, and doesn't directly stop the destructive enzyme. That's where alvelestat comes in. It's an oral neutrophil elastase inhibitor, which means it blocks the very enzyme doing the damage. A daily pill instead of weekly infusions; a targeted strike instead of a crude patch.
How the Deal Actually Works
This isn't a straightforward acquisition. It's more like a real estate option: Sentynl is paying for the right to buy U.S. commercial rights later, without committing to the full purchase price upfront. That's a smart structure when a drug still needs to pass its biggest test.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The breakdown looks like this. Sentynl pays an undisclosed upfront option fee now. If it exercises the option, Mereo can receive up to $40 million in upfront and R&D payments through the point of filing for FDA approval. On top of that, Mereo is eligible for up to $435 million in regulatory and commercial milestones, plus double-digit tiered royalties on U.S. net sales.
Meanwhile, Mereo keeps all rights outside the U.S. and leads the global Phase 3 development program, including regulatory interactions. Sentynl picks up global manufacturing rights, which gives Zydus's manufacturing muscle a role even before the drug hits the market.
It's a classic "you build it, we'll sell it" arrangement, with enough skin in the game from both sides to keep everyone motivated.
Why Sentynl Is on a Rare Disease Shopping Spree
This deal didn't come out of nowhere. Zydus has been quietly assembling a rare disease portfolio through Sentynl since acquiring the company back in 2017. The original play was U.S. specialty pain. But in 2024, the strategy pivoted hard toward ultra-rare diseases.
That year, Sentynl scooped up Zokinvy, an approved treatment for progeria (the rapid aging disease), for about $45.2 million in base price. It also grabbed CUTX-101, a treatment for Menkes disease, from Cyprium. In 2026, it added Progerinin (SLC-D011), yet another rare disease asset.
See the pattern? Sentynl is buying assets that already have clinical validation, regulatory history, or outright approvals. It's like shopping at the clearance rack of Western biotech: picking up proven goods at prices that mega-pharma wouldn't bother with, because the patient populations are too small to move the needle for a $200 billion company.
For Zydus, those small patient populations are features, not bugs. Orphan drugs carry premium pricing, reduced competition, and regulatory incentives. Stack enough of them together, and you've got a specialty pharma franchise that throws off serious margins.
The Alvelestat Bet: What Still Needs to Go Right
Alvelestat has completed two Phase 2 studies in severe AATD-LD. The results showed the drug successfully inhibited neutrophil elastase, improved biomarkers, and showed favorable trends in patient symptoms. It also picked up a positive orphan designation opinion from the European Medicines Agency in January 2025.
But Phase 2 data and Phase 3 success are two very different things. The companies expect to kick off the global Phase 3 trial in early 2027, and they'll use the option period to nail down manufacturing plans and study design.
This is where the option structure really earns its keep. Sentynl doesn't have to commit fully until it sees more data. If Phase 3 stumbles, the option fee is the extent of the damage. If Phase 3 succeeds, Sentynl has locked in U.S. rights to what could be the first oral therapy for Alpha-1 lung disease at a price negotiated before the data read out. That's the biotech equivalent of buying a house before the neighborhood gentrifies.
The Bigger Picture: India's Pharma Ambitions Go Global
Zoom out, and this deal fits a much larger trend. Indian pharmaceutical companies sharply increased their outbound M&A activity in 2025, and 2026 is continuing that momentum. The playbook: buy late-stage or commercial-stage Western assets with proven regulatory pathways, rather than gambling on early-stage science.
Global pharma buyers across the board are paying premium prices for rare disease assets right now. Indian companies like Zydus are competing for these types of assets, often using structured deal terms (options, milestones, royalties) to bridge valuation gaps and manage risk.
The strategic logic is clear: India has world-class manufacturing capabilities and cost discipline, but historically lacked access to high-margin specialty products in Western markets. Acquiring proven rare disease assets is the fastest way to close that gap.
The Bottom Line
Sentynl called this deal a "pivotal moment" for its rare disease strategy, and for once, the corporate superlative might be earned. Alvelestat addresses a real unmet need with a clear mechanism, the deal structure protects the downside, and the asset fits neatly into a portfolio that Zydus has been deliberately building for years.
The headline number is aspirational; most of it sits behind Phase 3 success and commercial milestones that haven't happened yet. But that's the nature of biotech dealmaking. You're buying lottery tickets with better odds than most, and Zydus has been picking its numbers carefully.
Deals & M&A5 min read
Radioactive Real Estate Just Got Its Biggest Buyer Ever
Curium's $8 billion bid for Lantheus would create the largest radiopharmaceutical company ever assembled. With big pharma already pouring billions into nuclear medicine, this deal could reshape how cancer gets diagnosed and treated.
